22 November 2017
News and Views
Links and Services
This month's Gastroenterology examines one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy trial.
Nonalcoholic steatohepatitis is a liver disease that complicates insulin-resistant states.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors